- Home
- GYRE
as of 02-27-2026 3:23pm EST
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 759.1M | IPO Year: | 2004 |
| Target Price: | $17.00 | AVG Volume (30 days): | 58.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | 0.04 | EPS Growth: | 103.55 |
| 52 Week Low/High: | $6.11 - $13.47 | Next Earning Date: | N/A |
| Revenue: | $275,000 | Revenue Growth: | -92.42% |
| Revenue Growth (this year): | 11.59% | Revenue Growth (next year): | 26.31% |
| P/E Ratio: | 214.38 | Index: | N/A |
| Free Cash Flow: | -5956000.0 | FCF Growth: | N/A |
AI-Powered GYRE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare GYRE vs Leading Stocks
See how GYRE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GYRE Gyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.